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Summary
We have observed previously that micronutrient supplementation
ameliorated suppression of a-defensin expression during diarrhoea.
However, how interactions between anti-microbial peptide (AMP)
expression and diarrhoeal disease are altered by micronutrient
supplementation remain unclear. Using oral vaccination as a model of
intestinal infection, we measured changes in AMP expression during
multiple micronutrient supplementation. In the first part, volunteers
underwent duodenal jejunal biopsy before and at 1, 2, 4 or 7 days after
administration of one of three live, attenuated oral vaccines against
rotavirus, typhoid and enterotoxigenic Escherichia coli. In the second part,
participants were randomized to receive a multiple micronutrient
supplement or placebo for 6 weeks before undergoing intestinal biopsy,
vaccination against typhoid and rebiopsy after 14 days. Expression of
human alpha-defensin (HD)5, HD6, hBD1, hBD2 and LL-37 was measured
by quantitative reverse transcription–polymerase chain reaction. Taken
together, the bacterial vaccines, but not rotavirus vaccine, reduced HD5
expression (P5 002, signed-rank test) and reduced LL-37 expression in
seven of the eight individuals whose biopsies had expression prevaccination
(P5 003). hBD2 was not detected. In the controlled trial, HD5 and HD6
expression after vaccination was lower [median ratio 05, interquartile range
(IQR)5 007–22 and 058, IQR5 013–23, respectively] than before
vaccination. There was no significant effect detected of micronutrient
supplementation on expression of HD5, HD6, hBD1 or LL-37. We conclude
that live attenuated bacterial vaccines, but not rotavirus vaccine, can reduce
intestinal a-defensins, and typhoid vaccine reduced LL-37 expression. We
found no evidence that micronutrient supplementation in the short term
had any impact on anti-microbial peptide expression.
Keywords: anti-microbial peptides, defensins, micronutrients, oral vaccines,
zinc
Introduction
Diarrhoeal disease remains a major cause of morbidity and
mortality in children throughout the tropics and in HIV
infection [1,2], yet host defence against intestinal patho-
gens remains poorly understood. There is also no clear
explanation for the reduced efficacy of oral vaccines in
tropical settings. Rotavirus vaccine is half as effective in
Malawi as in the United States [3,4]. Oral polio vaccine
may have only one-fifth the efficacy in India that it does in
Europe and North America [5]. Nutritional impairments
have been postulated as possible explanations. Concurrent-
and/or co-incident infections may also interfere with
induction of responses to vaccine antigens [6].
We have shown previously that human alpha-defensin
(HD)5 and HD6 expression were reduced in adults living
in Lusaka, Zambia compared to adults living in London,
UK [7]. Anti-microbial peptide (AMP) expression is
impaired during human shigellosis [8] and during
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diarrhoeal disease in Zambian adults [9]. Lower expression
of HD5 in women appeared to correlate with an increased
risk of diarrhoea [10]. In animal models, expression of a-
defensins is impaired during salmonellosis [11], yet in mice
which are normally susceptible to salmonella protection
can be conferred by transgenic expression of a human
intestinal a-defensin [11]. Mice which cannot cleave a-
defensins to their active form remain highly susceptible to
infection [12]. We have demonstrated previously that Pan-
eth cell granule abnormalities are associated with reduced
plasma zinc concentrations [13], and we postulated that
one possible mechanism of the well-established beneficial
effect of zinc for diarrhoeal disease [14] may be to improve
Paneth cell function in terms of increased expression of the
a-defensins HD5 and HD6.
In order to explore further the interaction between
micronutrients, intestinal colonization and anti-microbial
peptide-mediated host defence, we used oral vaccination as
a model of intestinal colonization. We describe this work in
two stages: exploration of the time–course of changes fol-
lowing administration of three oral vaccines, then a
randomized controlled trial of micronutrient supplementa-
tion and its effects on these changes. The safety of these
vaccines in this trial [15] and the effects of the micronu-
trient supplement on mucosal architecture have already
been published [16].
Study setting and methods
Two consecutive studies were carried out in adult volunteers
in Misisi, Lusaka, Zambia between February 2008 and April
2010. In the first study, three live, attenuated vaccines (Viv-
otif, ACAM2017 or Rotarix) were given orally to determine
the time–course of changes in anti-microbial peptide gene
expression following vaccination. In the second study, par-
ticipants were randomized to micronutrient supplementa-
tion or placebo for 6 weeks prior to administration of one
of the three vaccines, Vivotif. In both studies, the primary
end-point was the change in mRNA expression of five key
anti-microbial peptide genes in small intestinal biopsies.
Approval for both studies was obtained from the University
of Zambia Biomedical Research Ethics Committee (007-10-
07). The trial was registered as ISRCTN68751738.
Participants
Volunteers were recruited from a group of 157 residents liv-
ing in Misisi, Lusaka (the study population has been
described previously [13,15,17]). Inclusion criteria
included age between 18 and 60 years and the only exclu-
sion criterion was helminth infection [17]. Participants
who were pregnant, lactating, had had vaccination within 6
months, had taken antibiotics or non-steroidal anti-inflam-
matory drugs (NSAIDs) within 2 weeks or who had had
diarrhoea within 1 month were deferred until their
temporary exclusion criterion had elapsed. Informed con-
sent followed a three-stage process: door-to-door notifica-
tion, focus group discussions and individual counselling
leading to written consent.
In the first study (Fig. 1a), participants were randomized
to receive Vivotif (n5 23), ACAM2017 (n5 19) or Rotarix
vaccine (n5 24). Participants underwent enteroscopy
under sedation using an Olympus SIF-10 enteroscope to
obtain jejunal biopsies as described previously [10] on the
day prior to vaccination and 1, 2, 4 or 7 days afterwards.
Each participant underwent endoscopy only twice.
In the second study (Fig. 1b), participants were allocated
randomly to receive a multiple micronutrient supplement
or a matching placebo for 6 weeks. After this, they under-
went duodenal biopsy using a Pentax FG-29 gastroscope
(as the enteroscope was no longer in service). Participants
were then immunized with a full course (three doses) of
Vivotif typhoid vaccine, and were rebiopsied after 14 days.
Randomization, blinding and evaluation of end-points are
explained below. The decision to perform only two endos-
copies and collect two sets of biopsies was made to restrict
the number of endoscopies to two per participant. In sum-
mary, one set of endoscopic biopsies was collected after 6
weeks of trial supplementation, and one after a further 14
days following vaccination, during which period supple-
mentation was continued.
Vaccines
Vivotif (Ty21a vaccine; Berna Biotech, Bern, Switzerland) is
the only licensed oral typhoid vaccine [18,19]. It was
administered as a capsule: a single dose was given to those
participants scheduled to undergo rebiopsy after a 1- or 2-
day interval; two doses were given to those scheduled for
rebiopsy after 4 days; and three doses to those scheduled
for rebiopsies after 7 days or more. Altogether, 81 partici-
pants received Vivotif in parts 1 or part 2. ACAM2017
(Acambis PLC, Cambridge, UK) was derived from a spon-
taneous labile enterotoxin (LT)-negative enterotoxigenic
Escherichia coli (ETEC) isolate from Egypt, which has dele-
tions of the aromatase gene aroC and the membrane pro-
teins ompC and ompF, in addition to its spontaneous
deletions of toxin genes for LT, stable enterotoxin (ST) and
enteroaggregative ST (EAST). As ACAM2017 has had the
gene for CS1 [20] added, it expresses the colonization fac-
tor antigen II (CFA/II) antigens CS1, CS2 and CS3. In pre-
vious studies in London we established that ACAM2017
induces specific mucosal immunoglobulin (Ig)A against
CFA/I and CS1, CS2 and CS3 [20]. The dose of viable
organisms in the vaccine vials (3 3 1010) was confirmed in
the laboratory in three test vials which were then discarded
in order to avoid contamination of other vials used for vac-
cination. The dose contained in each vial was administered
as one dose and the vial was then discarded. Rotarix
(GlaxoSmithKline, Rixensart, Belgium) is a licensed vaccine
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against the G1P(8) strain of rotavirus; it was administered
as a single dose in 13 ml liquid carbonate buffer to all par-
ticipants, according to the manufacturer’s instructions.
Allocation to vaccines in the first study was not determined
by any clinical criteria, nor was completely random, but
was determined by availability at a particular date in the
study, previous exposure to vaccines (no participant was
given a vaccine which they had received previously) and
the temporary exclusion criteria listed above.
Micronutrient supplementation; randomization and
clinical trial design
The composition of the micronutrient (MM) supplement
(Immunace; Vitabiotics, London, UK) is shown in Table 1
and compared to recommended nutrient intakes [21]. Both
MM and placebo were manufactured and packaged in plas-
tic light-proof bottles labelled only with letters of the four-
letter code (A, B, C, D) held by the manufacturer until the
end of the trial, when the databases had been locked. Par-
ticipants were randomized to one of these four letters using
a computer-generated sequence, so although this four-
letter code was known to the study team, the contents of
the bottles and thus treatment allocation was masked from
both participants and study team. Participants were given
the masked micronutrient or placebo supplement for 6
weeks, then underwent endoscopy for distal duodenal
biopsy using a Pentax FG-29 gastroscope. Following this,
they were given Vivotif vaccine (three doses) and rebiop-
sied after 14 days.
Analysis of mRNA expression
Intestinal biopsies were collected from jejunum in the first part
of the study and distal duodenum in the second study, and
processed as described previously [17]. Briefly, biopsies were
collected into Tri reagent and RNA was extracted. RNA was
reverse-transcribed (RT) using standard techniques and
Fig. 1. Flow diagrams for the flow of participants through (a) the first study and (b) the second study – the clinical trial. MM5multiple
micronutrient; DU5duodenal ulcer; GU5gastric ulcer.
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quantified by real-time polymerase chain reaction (PCR) in a
Corbett Rotor Gene 3000 thermal cycler. Five AMP genes were
measured: the a-defensins HD5 (DEFA5) and HD6 (DEFA6),
the b-defensins hBD1 (DEFB1) and hBD2 (DEFB2) and the
cathelicidin LL-37. Cytokeratin-19 and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) were used as positive
controls for epithelial cells. Supporting information, Table 1
shows sequences of primers used. The RT–PCR conditions are
described in Kapulu et al. [17]; briefly, RT–PCR was per-
formed using SYBR Green (Qiagen, Valencia, CA, USA) over
45 cycles of 958C, 608C and 728C. HD5 and HD6 were
expressed as transcripts/lg total RNA using plasmid standards,
as described previously [10]. cDNA from IL-1b-treated Caco-
2 cells was used as a positive control for all the gut RT–PCRs,
whereas molecular biology-grade water was used as negative
control. Expression of hBD1, hBD2 and LL-37 were measured
qualitatively (present/absent) in samples in which GAPDH
and cytokeratin (CK)-19 expression were obtained.
Paneth cell evaluation
Paneth cell counts and morphology were enumerated as
described previously [13,16]. Haematoxylin and eosin-
stained sections were prepared of duodenal tissue which
had been orientated carefully prior to fixation in the endos-
copy unit using a binocular microscope. Paneth cell counts
were obtained separately in the crypt base, deep crypt and
superficial crypt, and each section was evaluated for the
presence of granule depletion which was classified into
mild, moderate and severe, as described previously [13].
Data analysis
Expression of the a-defensins was quantified absolutely
(transcripts/lg total RNA) using a plasmid standard [9],
and the change in expression from baseline expressed as -
fold change (post-vaccination/prevaccination). Expression
of the b-defensins and LL-37 were expressed qualitatively
(present/absent). The primary end-point of the first study
was the time–course of changes in mRNA expression of the
five genes following vaccination. Changes in gene expres-
sion between first and second time-points (-fold changes)
were evaluated using Wilcoxon’s signed-rank test for quan-
titative expression or by McNemar’s test for present/absent
expression. The primary end-point of the second study
(the randomized controlled trial) was the change in the
mRNA of these genes after vaccination, and comparison of
these changes between intervention and placebo groups
was made using the Kruskal–Wallis test. In all the graphical
representations of data, each individual is represented as
one data point for each paired result (before/after
vaccination).
Results
Effect of vaccination on anti-microbial peptide
expression
In the first study, 64 participants were given one of three
vaccines. Their demographic and clinical characteristics
did not differ by vaccine allocation (Table 2). However,
baseline HD5 expression was higher in the Vivotif group.
The time–courses of changes in HD5 for the three vac-
cines are shown in Fig. 2. There was no significant trend
in HD5 and HD6 expression over time following individ-
ual vaccines, but administration of either bacterial vaccine
(Fig. 2a,b) was followed by a significant decrease of HD5
(P5 004 by Wilcoxon’s signed–rank test). Administration
of Vivotif had no effect on hBD1 expression, which
remained unchanged in the eight participants who had
expression before vaccination, but LL-37 expression was
lost after vaccination in seven of the eight participants
who showed expression prior to vaccination (P5 003 by
McNemar’s test). Rotarix had no net effect on hBD1 (of
13 who had expression, two lost expression and one
gained) or LL-37 expression (of 22 who showed expres-
sion, three lost expression and one gained). ACAM2017
also had no significant effect on hBD1 (one lost and one
Table 1. Micronutrient supplement used
Micronutrient Daily dose RNI [21]
b-carotene 6 mg 42 mg*
Retinol palmitate 16 mg 08 mg
Vitamin C 300 mg 40 mg
Vitamin E 80 mg 4 mg
Vitamin D 20 g 10 g†
Thiamin (B1) 36 mg 09 mg
Riboflavin (B2) 12 mg 13 mg
Pyridoxine (B6) 20 mg 14 mg
Niacin 54 mg 16 mg
Vitamin B12 28 g 15 g
Folic acid 10 mg 02 mg
Vitamin K 140 g  70 g
Pantothenic acid 40 mg 3 mg
Iron 16 mg 148 mg
Zinc 30 mg 95 mg
Copper 1 mg 12 mg
Selenium 350 g 75 g
Iodine 400 g 140 g
Magnesium 100 mg 300 mg
Manganese 8 mg 14 mg
Chromium 200 g 25 g
L-cystine 80 mg –
L-carnitine 60 mg –
Bioflavonoids 60 mg –
Composition of Immunace micronutrient supplement produced
by Vitabiotics, compared to reference nutrient intake (RNI) for Brit-
ish adults (men or women, whichever is the higher). *Equivalent to
700 lg/day retinol, which is the RNI for adult men. †Based on RNI
for older adults, no intake of preformed vitamin D can be quantified
as required for adults exposed to sun.
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gained) or LL37 expression (one lost and four gained).
hBD2 was not detected in any of the samples. In this part
of the work, and throughout both parts, no effect of HIV
was demonstrated on expression of these five anti-
microbial genes.
Effect of micronutrient supplementation on these
responses
In the second study (randomized controlled trial), 80 par-
ticipants were randomized to 6 weeks of micronutrient
Table 2. Baseline data of participants in the first part (time–course)
Vivotif
(n5 23)
ACAM2017
(n5 19)
Rotarix
(n5 24) P
Sex (M : F) 8 : 15 10 : 9 10 : 14 068
Age (years: median, IQR) 40 (29–50) 42 (35–56) 35 (29–41) 009
BCG scar (%) 17 (74) 15 (83) 18 (75) 087
HIV seropositive (%) 13 (57) 5 (26) 9 (38) 023
CD4 count in HIV positives (cells/ll) 424 (247–845) 307 (243–489) 412 (402–430) 031
BMI (kg/m2) 227 (191–261) 209 (187–246) 223 (193–269) 074
MUAC (cm) 29 (26–34) 27 (26–31) 29 (26–31) 068
Fat tissue (% body mass) 32 (26–44) 33 (28–40) 33 (25–38) 076
Grip strength (kg) 300 (280–354) 321 (264–404) 281 (248–342) 041
HD5 (log transcripts/lg total RNA) 53 (40–58) 40 (27–48) 38 (29–47) 0002
HD6 (log transcripts/lg total RNA) 45 (37–50) 40 (36–45) 38 (28–44) 007
hBD1 (% expression) 8 (35) 8 (42) 13 (54) 002
LL-37 (% expression) 9 (39) 5 (26) 22 (91) <0001
P-values refer to the differences in characteristics across all groups. BMI5 body mass index; IQR5 interquartile range; BCG – bacillus Calm-
ette–Guerin; MUAC5mid–upper arm circumference; HD5 human alpha-defensin; hBD15 human beta-defensin 1.
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Fig. 2. Time–course of changes in HD5
expression following vaccination. Each
participant was biopsied twice (prior to
vaccination and at one time-point afterwards)
and each point represents the difference in HD5
mRNA between those two biopsies. Note that
biopsies collected after 1 day were from
participants given only one dose of Vivotif;
biopsies collected after 4 days were given two
doses; biopsies collected after 7 days were given
three doses. There was no significant effect of the
number of doses on the response. (a) Time–
course of changes in HD5 expression following
vaccination against typhoid with Vivotif. (b)
Time–course of changes in HD5 expression
following vaccination against enterotoxigenic
Escherichia coli (ETEC) with ACAM2017. (c)
Time–course of changes in HD5 expression
following rotavirus vaccination with Rotarix.
Anti-microbial peptides and oral vaccines
VC 2016 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society
for Immunology, Clinical and Experimental Immunology, 186: 205–213
209
supplement or placebo administration, which was followed
(6 weeks after randomization) by baseline biopsy, then vac-
cination and then rebiopsy after a further 14 days. Baseline
data (obtained after 6 weeks in the trial but before vaccina-
tion) showed no difference in clinical characteristics
between supplement and placebo groups (Table 3), but
HD6 was increased in adults allocated to the control group
even before any vaccines were administered. As the first
endoscopy was after 6 weeks of supplement or placebo, this
baseline difference reflects the effects of the nutritional
supplement prior to any vaccine effect. Changes in defensin
expression in supplemented and placebo groups after vac-
cination did not differ by treatment allocation (Table 4).
Effect of micronutrients on Paneth cell numbers and
granule morphology
Paneth cell numbers and morphology before and after vac-
cination were evaluated in 19 patients in the placebo group
and 15 patients in the micronutrient group. In the
Table 3. Baseline data at date of randomization – clinical trial
Vaccinees Controls
P
MM
(n5 23)
Placebo
(n5 23)
MM
(n5 8)
Placebo
(n5 10)
Sex (M : F) 8 : 15 8 : 15 4 : 4 1 : 9 100
Age (years: median, IQR) 38 (26–41) 42 (34–50) 41 (30–54) 42 (30–48) 044
BCG scar (%) 19 (83) 16 (73) 8 (89) 9 (82) 074
HIV seropositive (%) 8 (35) 12 (52) 4 (44) 6 (55) 079
CD4 count in HIV positives (cells/ll) 424 (247–845) 307 (243–489) 412 (402–430) 313 (245–670) 072
BMI (kg/m2) 223 (203–274) 228 (190–255) 200 (199–224) 203 (191–243) 025
MUAC (cm) 295 (270–33) 280 (260–320) 270 (260–320) 280 (270–300) 071
Fat tissue (% body mass) 34 (29–41) 36 (32–41) 32 (26–38) 31 (28–33) 004
Grip strength (kg) 313 (276–354) 321 (279–359) 311 (236–406) 281 (235–341) 040
P-value refers to difference between participants allocated to vaccination or not. BMI5 body mass index; IQR5 interquartile range; BCG –
bacillus Calmette–Guerin; MM5micronutrient; MUAC5mid–upper arm circumference.
Table 4. Anti-microbial peptide expression after 6 weeks of trial supplementation
Vaccinees Non-vaccinated P
(within
vaccinated
group)
P
(within
non-vaccinated
group)
P
(between
vaccinated and
non-vaccinated)
MM
(n5 23)
Placebo
(n5 23)
MM
(n5 8)
Placebo
(n5 10)
Before vaccination – baseline values
HD5 (log transcripts/
lg)
64 (54–69) 71 (59–75) 72 (67–74) 76 (64–86) 016 018 003
HD6 (log transcripts/
lg)
67 (61–75) 69 (62–74) 64 (56–72) 77 (67–84) 087 002 031
hBD1 (% expression) 7 (30) 8 (35) 2 (22) 2 (18) 100 100 055
hBD2 (expression) 0 0 0 0 –
LL-37 (% expression) 9 (39) 5 (22) 1 (11) 0 034 044 0048
14 days after vaccination – change following vaccination
HD5 (-fold change) 060 (017–408) 050 (007–22) 012 (004–38) 045 (012–154) 047 033 036
HD6 (-fold change) 100 (022–261) 060 (013–229) 196 (003–51) 034 (022–062) 036 037 077
hBD1 (expression
gained : expression
lost)
1 : 1 0 : 1 0 : 1 0 : 2 100 100 100
LL-37 (expression
gained : expression
lost)
2 : 5 4 : 4 2 : 0 2 : 0 100 100 045
Human alpha-defensin (HD)5 and HD6 expression are shown as median [interquartile range (IQR)] log transcripts/lg total RNA at baseline,
and after intervention as median (IQR) –fold change in log transcripts/lg total RNA (up-regulation> 10, down-regulation< 10). MM5micro-
nutrient; hBD15 human beta-defensin 1.
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remainder, either one of the pair of sections was not suita-
ble for evaluation. Median [interquartile range (IQR)] Pan-
eth cell counts in the basal zone, in biopsies taken
prevaccination but after 6 weeks of trial supplements, were
22 (16, 30) in the placebo group and 23 (15, 39) in the
micronutrient group (P5 092). Changes in Paneth cell
counts following vaccination were 012 (2063, 058) in
the placebo group and 013 (2046, 092) in the micronu-
trient group (P5 050). Paneth cell granule depletion was
apparent in 12 of the placebo group (two mild, eight mod-
erate, two severe) and 10 (0 mild, six moderate, four
severe) of the micronutrient group (P5 10 by Fisher’s
exact test).
Discussion
The ability to augment intestinal innate immunity might
have considerable impact upon treatment of persistent
diarrhoea which is a common cause, and complication
of, malnutrition [22,23]. Given the evidence that Paneth
cell function is zinc-dependent [13], we postulated that
a zinc-containing micronutrient supplement could aug-
ment synthesis of a-defensins, and possibly b-defensins
and LL-37, in small intestine. This non-specific effect of
vaccines on innate immunity has been shown with oral
polio virus and bacillus Calmette–Guerin (BCG) vacci-
nation [24]. In view of the difficulties in conducting
these studies in children, we carried out this study in
adults. We used oral vaccination as a model of coloniza-
tion, and showed that anti-microbial peptide expression
was down-regulated after vaccination with bacterial, but
not rotavirus, vaccines. We then analysed the effect of
micronutrient supplementation in a small Phase II
randomized controlled trial, and could detect no effect
in preventing the down-regulation. However, micronu-
trients increased the expression of HD6 before vaccina-
tion in the control group only. It is not clear why this
effect was not seen in the vaccination group, as this
baseline measurement was made before the vaccines
were administered.
We have reported previously that a-defensin expression
is down-regulated during diarrhoeal disease, and that
micronutrient supplementation protected against this [9].
A study carried out in Bangladesh at about the same time
as our earlier study suggested that hBD2 mRNA (but not
peptide) expression is increased during acute diarrhoea
(mainly cholera and enterotoxigenic E. coli) in adults, and
that HD5 peptide (but not mRNA) is reduced [25]. Taken
together, these data suggest that HD5 expression is reduced
by the impact of pathogen colonization. Conversely, the
anti-microbial molecules which are not Paneth cell prod-
ucts appear to be up-regulated during intestinal infection
[25,26], although we could not detect such an effect in this
African population. Further work is needed to resolve this
issue.
Based on our earlier study on the effect of micronu-
trient supplementation on AMP gene expression [9], we
hypothesized that the earlier result observed might be
demonstrable in a formal randomized controlled trial,
and we set up this study to detect an increase in AMP
expression over 1–2 weeks. We employed a higher dose
of micronutrients than in the previous study, although
for a much shorter duration (6 weeks instead of 2 years),
but the supplement was given in a trial period leading
up to a timed intervention rather than measuring inci-
dent episodes of diarrhoea, as in the previous study.
However, no effect was seen of the supplementation on
a-defensin mRNA. It is distinctly possible that the dura-
tion of supplementation was too short to observe an
effect on defensin gene expression, and this remains a
limitation of the study. Despite observational data sug-
gesting that Paneth cell degranulation was associated with
zinc depletion [13], we were unable to detect an effect of
zinc supplementation on Paneth cell granule morphology
or on a-defensin mRNA.
HD5 and HD6 were two orders of magnitude higher in
the second part of the study, the controlled trial. We postu-
late that this was due to using duodenal rather than jejunal
biopsies, a change which was necessitated by technical
issues with the serviceability of the enteroscope we had
used until 2009. The biopsy forceps used with the entero-
scope take smaller biopsies from the jejunum than is possi-
ble using the larger gastroscopy biopsy forceps for
duodenal biopsies. However, comparisons within each part
of the study showed consistent effects and we doubt that
this reduced the validity of the results.
The micronutrient which we postulated to be likely to
have the greatest impact upon innate immunity (Paneth
cell characteristics or AMP gene expression) was zinc, but
we could detect very little effect. This is consistent with
work in piglets, in which zinc had only minimal effects on
mucosal innate immunity [27]. Other studies have
reported effects of vitamin D on LL-37 expression [28];
however, consistent with our previous trial [9], we were
unable to detect such an effect. Whether this suggests that
baseline vitamin D status is satisfactory in this part of
Africa will require further work.
In conclusion, we report here a differential effect on
AMP gene peptide expression as a result of vaccine type.
These data are consistent with the hypothesis that the
nature of the mucosal innate immune response to live
attenuated oral vaccines, and the impact of vaccines on
anti-microbial defences, are part of a package of
responses which are determined by the nature of the
antigens present in the vaccine. Whether such properties
can be exploited for rational design of mucosal adjuvants
remains to be seen. For instance, rotavirus vaccine con-
fers protection against disease largely through specific
IgA secretion into the gut, without a major cell-mediated
immune response [29,30], while Vivotif induces strong T
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helper type 1 (Th1)-dominant cell-mediated immunity
[19]. Thus, this might have implications on the efficacy
of the vaccines due to the mode of vaccine-induced pro-
tection. We also report that there was no evidence that
micronutrient supplementation in the short term had
any impact on anti-microbial peptide gene expression.
Perhaps counterintuitively, but entirely consistent with
our previous findings [9,10], HIV had no impact upon
anti-microbial gene expression.
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